Actuate Therapeutics Management
Management criteria checks 1/4
Actuate Therapeutics' CEO is Dan Schmitt, appointed in Mar 2015, has a tenure of 9.92 years. total yearly compensation is $5.58M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 2.93% of the company’s shares, worth $4.27M. The average tenure of the management team and the board of directors is 2.8 years and 2.4 years respectively.
Key information
Dan Schmitt
Chief executive officer
US$5.6m
Total compensation
| CEO salary percentage | 7.2% |
| CEO tenure | 10yrs |
| CEO ownership | 2.9% |
| Management average tenure | 2.8yrs |
| Board average tenure | 2.4yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$6m | US$400k | -US$27m |
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$29m |
| Mar 31 2024 | n/a | n/a | -US$28m |
| Dec 31 2023 | US$520k | US$400k | -US$25m |
Compensation vs Market: Dan's total compensation ($USD5.58M) is above average for companies of similar size in the US market ($USD638.32K).
Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.
CEO
Dan Schmitt (61 yo)
10yrs
Tenure
US$5,578,616
Compensation
Mr. Daniel M. Schmitt, also known as Dan, serves as Chief Executive Officer and President at Actuate Therapeutics, Inc. since March 2015. Mr. Schmitt served as Chief Operating Officer of Genus Oncology, LL...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 10yrs | US$5.58m | 2.93% $ 4.3m | |
| Co-Founder & COO | 2.8yrs | US$675.00k | 0.53% $ 779.0k | |
| Chief Financial Officer | 1.1yrs | US$1.92m | no data | |
| Scientific Founder and Advisor | no data | no data | no data |
2.8yrs
Average Tenure
61.5yo
Average Age
Experienced Management: ACTU's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.9yrs | US$5.58m | 2.93% $ 4.3m | |
| Independent Director | 2.5yrs | US$111.24k | 10.54% $ 15.4m | |
| Member of Scientific Advisory Board | 2.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.4yrs | no data | no data | |
| Independent Director | 4yrs | US$115.85k | 0.39% $ 569.6k | |
| Independent Director | less than a year | US$213.11k | no data | |
| Independent Director | less than a year | US$213.11k | no data | |
| Independent Chairman | 9.9yrs | US$124.31k | 0.39% $ 575.1k | |
| Independent Director | less than a year | US$214.76k | no data | |
| Member of Scientific Advisory Board | 2.4yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.4yrs
Average Tenure
53yo
Average Age
Experienced Board: ACTU's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/19 09:11 |
| End of Day Share Price | 2025/03/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Actuate Therapeutics, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Christopher Liu | Lucid Capital Markets |